IDYA vs. MLTX, XENE, CRNX, FOLD, ACAD, HCM, ARWR, INDV, ARVN, and PBH
Should you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include MoonLake Immunotherapeutics (MLTX), Xenon Pharmaceuticals (XENE), Crinetics Pharmaceuticals (CRNX), Amicus Therapeutics (FOLD), ACADIA Pharmaceuticals (ACAD), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Indivior (INDV), Arvinas (ARVN), and Prestige Consumer Healthcare (PBH). These companies are all part of the "pharmaceutical preparations" industry.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to MoonLake Immunotherapeutics' net margin of -483.05%. IDEAYA Biosciences' return on equity of -9.22% beat MoonLake Immunotherapeutics' return on equity.
In the previous week, IDEAYA Biosciences had 2 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 2 mentions for MoonLake Immunotherapeutics. IDEAYA Biosciences' average media sentiment score of 0.83 beat MoonLake Immunotherapeutics' score of 0.80 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
IDEAYA Biosciences received 70 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 76.36% of users gave MoonLake Immunotherapeutics an outperform vote while only 67.47% of users gave IDEAYA Biosciences an outperform vote.
MoonLake Immunotherapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
MoonLake Immunotherapeutics presently has a consensus price target of $73.42, indicating a potential upside of 46.22%. IDEAYA Biosciences has a consensus price target of $44.55, indicating a potential upside of 2.85%. Given IDEAYA Biosciences' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than IDEAYA Biosciences.
93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 15.3% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 5.1% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
MoonLake Immunotherapeutics has higher earnings, but lower revenue than IDEAYA Biosciences. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
MoonLake Immunotherapeutics beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.
Get IDEAYA Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
IDEAYA Biosciences Competitors List
Related Companies and Tools